Corbus Pharmaceuticals (CRBP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ...

Corbus Pharmaceuticals (CRBP) has been on a downward spiral lately with significant selling pressure. After declining 22.9% over the past four weeks, the stock looks well positioned for a trend ...

This was the stock's second consecutive day of losses.

Shares of CRBP stock opened at $6.96 on Monday. The firm’s 50-day simple moving average is $9.32 and its 200-day simple moving average is $18.10. Corbus Pharmaceuticals has a 1-year low of $6.38 ...

Equities research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for shares of Corbus Pharmaceuticals in a research note issued to investors on Wednesday, March ...